Advertisement

Lisa Newman, MD, MPH, FACS, FASCO, Appointed Chief of Breast Surgery at NewYork-Presbyterian


Advertisement
Get Permission

Lisa Newman, MD, MPH, FACS, FASCO

Lisa Newman, MD, MPH, FACS, FASCO

Lisa Newman, MD, MPH, FACS, FASCO, breast surgeon and researcher, has been appointed Chief of the Section of Breast Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine. In her new role, which began at the end of August, Dr. Newman will lead multidisciplinary breast oncology programs and provide care to women and men affected by breast cancer.

Dr. Newman will also head a team of breast surgeons that uses novel screening and imaging technologies, innovative surgical and reconstruction techniques, and radiation therapies to provide patients with comprehensive breast cancer care. In addition, Dr. Newman will seek to expand research efforts of the Section of Breast Surgery and will foster the mentorship and training of the next generation of breast surgeons. She will also broaden regional as well as international breast health outreach and education through global cancer initiatives.

In addition, Dr. Newman will supervise the Breast Surgical Oncology Program at NewYork-Presbyterian Lower Manhattan Hospital, NewYork-Presbyterian Brooklyn Methodist Hospital, and NewYork-Presbyterian Queens. Her goal is to provide a multidisciplinary approach to breast cancer treatment through a standardized clinic and tumor board system implemented in each hospital, so patients receive the same high-quality care and have equally optimal experiences and outcomes across the boroughs.

Research Focus

In addition to her clinical practice, Dr. Newman investigates how and why breast cancer risk and disease outcomes vary based upon patients’ race and ethnicity. She is particularly interested in the genetics of aggressive breast tumors, especially in triple-negative breast cancer. In 2006, Dr. Newman launched the International Center for the Study of Breast Cancer Subtypes to identify the genetic origins of triple-negative breast cancer and determine why it particularly affects women of African descent. This program, which will relocate to NewYork-Presbyterian and Weill Cornell Medicine, will continue to provide medical supplies and training opportunities to its partners in the United States, Africa, the Caribbean, and India while focusing on breast cancer incidence around the world. ■


Advertisement

Advertisement




Advertisement